Rice Hall James & Associates LLC Sells 24,454 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Rice Hall James & Associates LLC decreased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 10.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 210,622 shares of the medical instruments supplier's stock after selling 24,454 shares during the quarter. LeMaitre Vascular makes up approximately 1.0% of Rice Hall James & Associates LLC's portfolio, making the stock its 27th largest position. Rice Hall James & Associates LLC owned about 0.93% of LeMaitre Vascular worth $17,671,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LMAT. Raymond James Financial Inc. bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth $14,900,000. Rockefeller Capital Management L.P. bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth $7,787,000. Segall Bryant & Hamill LLC bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth $5,446,000. Invesco Ltd. grew its stake in shares of LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after acquiring an additional 58,720 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of LeMaitre Vascular by 7,486.5% in the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock worth $4,519,000 after acquiring an additional 53,154 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 0.6%

Shares of NASDAQ LMAT traded down $0.51 during trading on Thursday, hitting $82.10. The stock had a trading volume of 135,425 shares, compared to its average volume of 169,058. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83. The company has a market capitalization of $1.85 billion, a PE ratio of 41.46, a PEG ratio of 2.18 and a beta of 0.82. The firm has a fifty day moving average of $82.83 and a two-hundred day moving average of $87.86.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The business's revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.44 EPS. As a group, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.97%. LeMaitre Vascular's payout ratio is currently 40.40%.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 76,868 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer owned 1,796,783 shares in the company, valued at approximately $154,146,013.57. This represents a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 100,000 shares of company stock worth $8,556,857 in the last three months. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.